SGLT2 inhibitors alleviated podocyte damage in lupus nephritis by decreasing inflammation and enhancing autophagy

The protective role of sodium glucose cotransporter 2 (SGLT2) inhibitors in renal outcomes has been revealed by large cardiovascular outcome trials among patients with type 2 diabetes. However, the effect of SGLT2 inhibitors on lupus nephritis (LN) and its underlying mechanisms remain unknown. We ap...

Full description

Saved in:
Bibliographic Details
Published in:Annals of the rheumatic diseases 2023-10, Vol.82 (10), p.1-13
Main Authors: Zhao, Xin-yu, Li, Shuang-shuang, He, Ying-xin, Yan, Li-jie, Lv, Fu, Liang, Qi-meng, Gan, Yu-hui, Han, Li-pei, Xu, Hong-de, Li, Yong-chun, Qi, Yuan-yuan
Format: Article
Language:English
Subjects:
Animals
Anti-DNA antibodies
Antigens
Autophagy
Bioengineering
Biopsy
Clinical trials
Creatinine
CRISPR
Diabetes
Diabetes mellitus (non-insulin dependent)
Diabetes Mellitus, Type 2
Glomerular filtration rate
Glucose
Humans
Immunoglobulin G
Immunoglobulin G - metabolism
Immunosuppressive agents
Inflammation
Inflammation - pathology
Kidney - pathology
Kidney diseases
Laboratory animals
Lupus
Lupus nephritis
Lupus Nephritis - drug therapy
Mice
Mice, Inbred MRL lpr
Molecular modelling
Na+/glucose cotransporter
Nephritis
Nephrology
Podocytes - pathology
Proteins
Proteinuria
Renal function
Sodium-Glucose Transporter 2 - metabolism
Sodium-Glucose Transporter 2 Inhibitors - pharmacology
Sodium-Glucose Transporter 2 Inhibitors - therapeutic use
Urine
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!